All In Biotech

Drug Trial Radar · NCT07228390

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB (PF-06651600) IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 128 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

128

Actual

Start

Nov 13, 2025

Primary completion

Dec 8, 2026

Study completion Jan 5, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of the study medicine (called Ritlecitinib) for the possible treatment of hidradenitis suppurativa (HS). HS is a disease causing long lasting painful red skin lumps. This study is seeking participants who: * have moderate or severe HS * have previously received antibiotics for HS that did not help, or could not tolerate antibiotics Participants will be randomly (like a flip of coin) assigned to receive either the study medicine or a placebo (a pill that looks like the study medicine but does not contain any medicine). The study medicine or placebo will be taken by mouth once daily at home. For the first part of the study, participants will receive a loading (starting) dose. For the next part of the study, participants will receive a maintenance (ongoing) dose. Participants will take part in the study for about 24 weeks (about 6 months). There will be about 10 study clinic visits: a screening visit, Day 1, and then every 1, 2, or 4 weeks until week 16. At each visit, participants will report on their health and have tests such as physical exams, blood and urine tests, vital signs, chest X-rays, ECGs, hearing tests, and questionnaires. Participants will record when they take the study medicine and their HS symptoms every day in an eDiary on a mobile phone. The experiences of participants receiving the study medicine will be compared to those receiving placebo to help see if the study medicine is safe and effective.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • RitlecitinibDrug

    Participants will receive one oral dose once daily (QD), starting with a loading dose of ritlecitinib for 8 weeks, followed by maintenance for 8 weeks.

  • PlaceboDrug

    Participant will receive matching placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Difference in proportion of responders based on Hidradenitis Suppurativa Clinical Response achieving at least 50% reduction from baseline (Hidradenitis Suppurativa Clinical Response HiSCR50) in patients with HS treated with ritlecitinib versus placebo.Time frame: Week 16

Locations

57 sites in 6 countries. Site status is shown where the registry gives one.

  • Burke Pharmaceutical Research

    Hot Springs, Arkansas

  • First OC Dermatology Research Inc

    Fountain Valley, California

  • Northridge Clinical Trials

    Northridge, California

  • Integrative Skin Science and Research

    Sacramento, California

  • Wolverine Clinical Trials

    Santa Ana, California

  • Skin Care Research

    Boca Raton, Florida

  • Olympian Clinical Research

    Largo, Florida

  • Ziaderm Research LLC

    North Miami Beach, Florida

  • D&H Tamarac Research Center

    Tamarac, Florida

  • NMC Research LLC

    Tampa, Florida

  • USF - Carol and Frank Morsani Center for Advanced Healthcare-Clinical Research Center

    Tampa, Florida

  • Alliance Clinical Research of Tampa

    Tampa, Florida

  • Olympian Clinical Research

    Tampa, Florida

  • USF Florida Hearing Clinic

    Tampa, Florida

  • TruDerm & TruSpa

    Wellington, Florida

  • Advanced Medical Research, PC.

    Sandy Springs, Georgia

  • Endeavor Health

    Skokie, Illinois

  • The Indiana Clinical Trials Center, PC

    Plainfield, Indiana

  • Options Research Group

    West Lafayette, Indiana

  • Essential Medical Research - Overland Park

    Overland Park, Kansas

  • Skin and Hair Center

    Overland Park, Kansas

  • DS Research of Kentucky

    Louisville, Kentucky

  • Revival Research Institute, LLC

    Southfield, Michigan

  • Revival Research Institute, LLC

    Troy, Michigan

  • Stracskin

    Portsmouth, New Hampshire

  • ClinOhio Research Services

    Columbus, Ohio

  • Columbia Dermatology & Aesthetics

    Columbia, South Carolina

  • Palmetto Clinical Trial Services - Greenville

    Greenville, South Carolina

  • Center for Clinical Studies, LTD. LLP

    Houston, Texas

  • Eurofins CRL

    Forest, Virginia

  • Centre de Recherche Saint-Louis inc.

    Québec, Canada

  • Dermatology Research Institute

    Calgary, Alberta, Canada

  • Laser Rejuvenation Clinics Edmonton D.T. Inc

    Edmonton, Alberta, Canada

  • Skin Physicians Dermatology

    Edmonton, Alberta, Canada

  • CaRe Clinic

    Red Deer, Alberta, Canada

  • Ryan Clinical Research Inc.

    Newmarket, Ontario, Canada

  • DAR Clinical Research

    Ottawa, Ontario, Canada

  • North York Research Inc

    Toronto, Ontario, Canada

  • FACET Dermatology

    Toronto, Ontario, Canada

  • Universitätsklinikum Frankfurt

    Frankfurt, Germany

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.